The congenital hyperinsulinism treatment market encompasses drugs and devices used for managing congenital hyperinsulinism, an autosomal dominant disease characterized by dysregulated insulin secretion. The treatment involves use of diazoxide to inhibit insulin secretion andoctreotide to delay gastric emptying. Surgery including partial pancreatectomy is performed in severe cases.
The global...
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian